SCHEMBL7948229

SCHEMBL7948229

CCn1nccc1C(=O)NC

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.60
MEN1 O00255 3/20 0.60
ALDH1A1 P00352 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MAPT P10636 2/20 0.60
NPSR1 Q6W5P4 2/20 0.60
HPGD P15428 1/20 0.60
RAB9A P51151 3/20 0.58
NPC1 O15118 2/20 0.58
HTT P42858 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.56
LMNA P02545 1/20 0.44
FLT1 P17948 4/20 0.43
KDR P35968 4/20 0.43
CYP2D6 P10635 1/20 0.43
POLB P06746 1/20 0.41
ABL1 P00519 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25457895 0.86 FLT1 (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL21617355 0.86 KMT2A (0.60) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL7515644 0.84 KMT2A (0.58) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL23010980 0.84 KMT2A (0.61) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL25110605 0.81 FLT1 (0.43) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL25660343 0.80 KMT2A (0.42) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL21904003 0.80 KMT2A (0.55) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL262196 0.79 MEN1 (0.53) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL336115 0.79 KMT2A (0.53) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL23384946 0.79 KMT2A (0.52) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023225664-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-11-23 WO disclosed
US-20230159465-A1 IMMUNOMODULATOR HITGEN INC. (CN) 2023-05-25 US disclosed
US-20200247785-A1 IL-17 Ligands And Uses Thereof DICE MOLECULES SV, INC. 2020-08-06 US disclosed
WO-2001049289-A1 PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS TEXAS BIOTECHNOLOGY CORPORATION (US) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159465-A1 IMMUNOMODULATOR IL2, IL17A, IL2RA KMT2A 4222/4885MEN1 3926/4885ALDH1A1 302/4885
US-20200247785-A1 IL-17 Ligands And Uses Thereof IL17A, IL2, IL15 KMT2A 4343/4885MEN1 2700/4885ALDH1A1 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.